AgomAb Therapeutics NV ADR (AGMB)
NASDAQ:AGMB
AGMB Stock Chart & Stats
$9.85
--
Market closed
$9.85
--
Day’s Range― - ―
52-Week Range$9.63 - $17.45
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$246.25K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.72
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,736,780
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.00Price Target Upside224.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AgomAb Therapeutics NV ADR News
AGMB FAQ
What was AgomAb Therapeutics NV ADR’s price range in the past 12 months?
AgomAb Therapeutics NV ADR lowest stock price was $9.63 and its highest was $17.45 in the past 12 months.
What is AgomAb Therapeutics NV ADR’s market cap?
AgomAb Therapeutics NV ADR’s market cap is $246.25K.
When is AgomAb Therapeutics NV ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AgomAb Therapeutics NV ADR’s earnings last quarter?
Currently, no data Available
Is AgomAb Therapeutics NV ADR overvalued?
According to Wall Street analysts AgomAb Therapeutics NV ADR’s price is currently Undervalued.
Does AgomAb Therapeutics NV ADR pay dividends?
AgomAb Therapeutics NV ADR does not currently pay dividends.
What is AgomAb Therapeutics NV ADR’s EPS estimate?
AgomAb Therapeutics NV ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AgomAb Therapeutics NV ADR have?
AgomAb Therapeutics NV ADR has 48,736,780 shares outstanding.
What happened to AgomAb Therapeutics NV ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AgomAb Therapeutics NV ADR?
Currently, no hedge funds are holding shares in AGMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AgomAb Therapeutics NV ADR
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
AGMB Stock 12 Month Forecast
Average Price Target
$32.00
▲(224.87% Upside)